NCT04524442 - Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

November 18, 2023

Study Completion Date

November 18, 2023

Conditions

Gastroenteropancreatic Neuroendocrine Tumors

Interventions

DRUG

arginine/lysine

1000 milliliters (mL) administered at a constant rate of 250 mL per hour

Trial Locations (7)

Erasmus University Medical Center, Rotterdam

Istituto Europeo di Oncologia, Milan

Gammed-Centrum Diagnostyczno-Lecznicze, Warsaw

University Hospitals Birmingham NHS Foundation Trust, Birmingham

University Hospitals Coventry & Warwickshire NHS Trust, Coventry

Royal Surrey Country Hospital, Guildford

Liverpool Royal Hospital, Liverpool